Ribavirin News and Research

RSS

Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.

Experts advise not to make COVID-19 crisis worse by rushing for cures

People have died from overdoses of unproven cures in past pandemics. In an editorial published today in Australian Prescriber, Associate Professor Darren Roberts from St Vincent’s Hospital in Sydney and Dr Alexandra Bennett from the NSW Therapeutic Advisory Group advise we should not make the current COVID-19 crisis worse by using medicines based on inadequate evidence.

11 May 2020

MU researcher finds four antiviral drugs effective in inhibiting novel coronavirus

Now, a researcher at the University of Missouri has found that four antiviral drugs, including remdesivir, a drug originally developed to treat Ebola, are effective in inhibiting the replication of the coronavirus causing COVID-19.

4 May 2020

COVID-19 can trigger serious inflammatory-related cardiovascular problems

The coronavirus disease (COVID-19) is potentially fatal for vulnerable populations like seniors who over 60 years old, and those with underlying medical conditions, like heart disease, diabetes, and lung disease. Reports show that patients are suffering from heart impairment caused by COVID-19. A new study sheds light on the effect of the novel coronavirus on the heart, causing cardiovascular problems, even in those without underlying heart conditions.

27 Apr 2020

Remdesivir drug stops novel coronavirus from replicating

Scientists from the University of Alberta have published findings that the antiviral drug remdesivir prevents replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by inhibiting RNA replication. The study, published in April 2020 in the Journal of Biological Chemistry, follows on the heels of earlier reports from the same lab in February, showing the drug's effectiveness against the related Middle East Respiratory Syndrome (MERS) virus.

15 Apr 2020

Patients with hypertension, diabetes and heart disease more likely to die from COVID-19

As the coronavirus disease (COVID-19) evolves, important information emerges, thanks to studies and analyses undertaken by scientists and health experts. With more data available based on patients in actual healthcare settings, scientists have more information on how the virus affects the body and who are at most risk of the disease.

2 Apr 2020

Updated USPSTF recommendations on hepatitis C screening

The U.S. Preventive Services Task Force (USPSTF) now recommends the hepatitis C virus (HCV) infection screening for adults in the age group 18 to 79 years. This update comes against the background of increasing HCV over the last ten years, primarily due to higher injection drug use, and closer monitoring. The recommendation ensures that this screening will be covered by insurance as well without cost-sharing.

2 Mar 2020

Researchers use big data to gain better understanding of hepatitis E virus

As far as research is concerned, hepatitis E had long led a shadowy existence - even though it is the main cause for acute viral inflammation of the liver.

18 Mar 2019

Measles can be deadly for people with weakened immune systems

Last year, a 26-year-old man receiving treatment for leukemia went to a Swiss hospital's emergency room with a fever, a sore throat, and a cough, and was admitted. His condition worsened, and 17 days later, he died from severe complications of measles.

1 Nov 2018

Researchers find possible active substance that may cure hepatitis E

An international team of researchers has now found a possible active substance against the virus in the naturally occurring substance silvestrol.

1 Aug 2018

U.S. FDA approves updated labeling for pan-genotypic single tablet regimen for HCV/HIV co-infected patients

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved updated labeling for Epclusa (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV.

1 Aug 2017

Scientists find new clues to how RSV causes disease

By age 2, most children have been infected with respiratory syncytial virus (RSV), which usually causes only mild cold symptoms. But people with weakened immune systems, such as infants and the elderly, can face serious complications, including pneumonia and -- in some cases -- death.

30 Jun 2017

Researchers study Lassa fever patient's immune response and viral persistence

When an American nurse working in West Africa became ill with Lassa fever and was evacuated to the U.S. for treatment in 2016, it provided a rare opportunity.

22 Jun 2017

FDA grants approval for two drugs to treat hepatitis C virus in children

The U.S. Food and Drug Administration today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were previously approved to treat HCV in adults.

7 Apr 2017

Hepatitis C virus sabotages antiviral defenses of liver cells by blunting effect of immune proteins

The virus that causes hepatitis C protects itself by blocking signals that call up immune defenses in liver cells, according to University of Washington researchers and colleagues reporting Nov. 14 in Nature Medicine.

17 Nov 2016

Epclusa drug receives FDA approval for treating adult patients with chronic HCV

The U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease).

28 Jun 2016

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

AbbVie, a global biopharmaceutical company, today announced that 91 percent (n=20/22) of genotype 1 (GT1) chronic hepatitis C virus (HCV) infected patients who failed previous therapy with direct-acting antivirals (DAAs) achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with ribavirin (RBV) in the primary intent-to-treat analysis.

15 Apr 2016

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

AbbVie, a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505 assessable for analysis) and 100 percent (n=53/53) of genotype 4 (GT4) patients achieved sustained virologic response at 12 weeks post-treatment (SVR12).

15 Apr 2016

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).

15 Apr 2016

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

Data from a new study show that patients with Hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver cancer,1 had a 'high rate' of re-developing their illness.

13 Apr 2016

PharmaEssentia to present results of P1101 + ribavirin phase II trial in HCV patients at APASL 2016

PharmaEssentia Corporation announces presentation of the results of the phase II trial for P1101 + ribavirin in patients with chronic HCV genotype 1 infection at the 25th Conference of the Asian Pacific Association for the Study of the Liver, taking place in Tokyo, Japan from February 20 to 24, 2016 (APASL 2016). Data will be presented by the study coordinating investigator Prof. Wan-Long Chuang (Taiwan) at the HCV parallel oral session on Feb 22nd (15:45-17:45).

22 Feb 2016

Ribavirin News and Research

Further Reading

Experts advise not to make COVID-19 crisis worse by rushing for cures

MU researcher finds four antiviral drugs effective in inhibiting novel coronavirus

COVID-19 can trigger serious inflammatory-related cardiovascular problems

Remdesivir drug stops novel coronavirus from replicating

Patients with hypertension, diabetes and heart disease more likely to die from COVID-19

Updated USPSTF recommendations on hepatitis C screening

Researchers use big data to gain better understanding of hepatitis E virus

Measles can be deadly for people with weakened immune systems

Researchers find possible active substance that may cure hepatitis E

U.S. FDA approves updated labeling for pan-genotypic single tablet regimen for HCV/HIV co-infected patients

Scientists find new clues to how RSV causes disease

Researchers study Lassa fever patient's immune response and viral persistence

FDA grants approval for two drugs to treat hepatitis C virus in children

Hepatitis C virus sabotages antiviral defenses of liver cells by blunting effect of immune proteins

Epclusa drug receives FDA approval for treating adult patients with chronic HCV

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

PharmaEssentia to present results of P1101 + ribavirin phase II trial in HCV patients at APASL 2016

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News